

In the Claims:

Applicants hereby submit a clean version of each replacement claim. Please enter each claim.

-
1. (amended) A process for selecting phage that are resistant to blood inactivation, comprising:
- mixing a blood component with a phage display library; and,
 - selecting for phage which are resistant to inactivation by the blood component.
2. (amended) A process for determining epitopes associated with specific parenchymal cells, comprising:
- preparing epitope display particles that are sized to exit a blood vessel and contact parenchymal cells;
 - inserting the epitope display particles into a blood vessel; and,
 - exposing the epitope display particles to the parenchymal cells where the epitope display particles associate with peptides specific to a cell;
 - identifying cell specific epitopes.
-
3. (amended) The process of claim 1 wherein selection comprises multiple rounds of selection.
4. (amended) The process of claim 1 wherein the phage display library comprises T7 phage.
5. (amended) The process of claim 1 wherein the blood component is mixed with the phage display library *in vitro*.
-
6. (amended) The process of claim 1 wherein the blood component is mixed with the phage display library *in vivo*.
7. The process of claim 1 wherein a variable part of the phage DNA sequence is identified.
8. (amended) A phage that inhibits inactivation by blood components, comprising a phage having a coat peptide that protects the phage from antibody attack and inactivation.
9. (amended) The phage of claim 8 wherein the coat peptide carboxy terminus comprises a lysine or an arginine.
10. (amended) The phage of claim 8 wherein the peptide comprises a clone 20-6 peptide.
11. (amended) The process of claim 1 further comprising determining phage coat peptide interactions with antibodies using the selected phage.
-
12. The process of claim 11 wherein the selected phage is affinity purified.

13. (amended) The process of claim 11 wherein a phage coat protein's sequence is determined
14. (amended) A peptide for complexing with a drug to protect the drug from antibody inactivation during delivery, comprising determining a phage coat peptide sequence from the phage selected in claim 1 and associating the peptide with the drug to be delivered.
15. (amended) The peptide of claim 14 wherein the peptide contains a carboxy terminal amino acid selected from the group consisting of arginine and lysine.
16. (amended) The peptide of claim 14 wherein the peptide contains a tyrosine.

Please amend claims 1-6, 8-11, and 13-16 as follows:

Version with markings to show changes made:

1. (Amended) [A process comprising: providing an epitope display system and exposing the epitope display system to blood products to identify useful epitopes.]

A process for selecting phage that are resistant to blood inactivation, comprising:

- a. mixing a blood component with a phage display library; and,
- b. selecting for phage which are resistant to inactivation by the blood component.

2. (Amended) [A process for selecting phage that is resistant to blood inactivation, comprising:

- a. mixing a blood component with a phage display;
- b. selecting a phage; and,
- c. growing the selected phage in bacteria.]

A process for determining epitopes associated with specific parenchymal cells, comprising:

- e. preparing epitope display particles that are sized to exit a blood vessel and contact parenchymal cells;
 - f. inserting the epitope display particles into a blood vessel; and,
 - g. exposing the epitope display particles to the parenchymal cells where the epitope display particles associate with peptides specific to a cell;
 - h. identifying cell specific epitopes.
4. (Amended) [The process of claim 1 wherein the phage display comprises multiple rounds of selection.]

The process of claim 1 wherein selection comprises multiple rounds of selection.

5. (Amended) [The process of claim 1 wherein the phage consists of a T7 phage.]

The process of claim 1 wherein the phage display library comprises T7 phage.

6. (Amended) [The process of claim 1 wherein the blood component is mixed with the phage display *in vitro*.]

The process of claim 1 wherein the blood component is mixed with the phage display library *in vitro*.

7. (Amended) [The process of claim 1 wherein the blood component is mixed with the phage display *in vivo*.]

The process of claim 1 wherein the blood component is mixed with the phage display library *in vivo*.

8. (Amended) [A peptide display library, comprising: a peptide that prevents phage inactivation.]

A phage that inhibits inactivation by blood components, comprising a phage having a coat peptide that protects the phage from antibody attack and inactivation.

9. (Amended) [The peptide display library of claim 8 wherein the peptide comprises lys+/arg+.]

The phage of claim 8 wherein the coat peptide carboxy terminus comprises a lysine or an arginine.

10. (Amended) [The peptide display library of claim 8 wherein the peptide comprises a clone 20-6 peptide.]

The phage of claim 8 wherein the peptide comprises a clone 20-6 peptide.

11. (Amended) [The process of claim 1 further comprising: selecting a phage resistant to inactivation and determining peptide-protein interactions using the selected phage.]

The process of claim 1 further comprising determining phage coat peptide interactions with antibodies using the selected phage.

13. (Amended) [The process of claim 11 wherein the protein's sequence is determined.]

The process of claim 11 wherein a phage coat protein's sequence is determined

14. (Amended) [A peptide specific for drug delivery, comprising: selecting a drug delivery peptide using the process of claim 1.]